Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx

Executive Summary

Company will seek CEO with experience in brand name drugs to succeed Alan Cohen, who is retiring. Cohen is expected to continue through the transition process

You may also be interested in...



Andrx CSO resigns

Andrx Chief Scientific Officer and Pharmaceuticals President Chih-Meng Chen, PhD, resigns. Chen will remain co-chairman of board and will work for Andrx as a consultant. His position as Andrx Pharma president will be temporarily filled by Exec VP and General Counsel Scott Lodin. Andrx is also looking for a CEO. The company announced in April that CEO Alan Cohen will retire (1"The Pink Sheet" April 16, p. 7)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel